Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 12/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 12/20 | 0.49 |
| ▸ | MPL | P40238 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562095 | 0.98 | FEN1 (0.48) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL31063587 | 0.98 | FEN1 (0.48) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL31063682 | 0.98 | FEN1 (0.48) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL38652286 | 0.94 | FEN1 (0.45) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL30747792 | 0.94 | FEN1 (0.46) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL31226795 | 0.94 | FEN1 (0.45) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL25261119 | 0.90 | FEN1 (0.58) | FEN1ALOX5APMPLKDM1ANPSR1 | |
| SCHEMBL30433595 | 0.88 | FEN1 (0.51) | FEN1ALOX5APKDM1A | |
| SCHEMBL30712826 | 0.87 | KDM1A (0.53) | FEN1ALOX5APMPLKDM1APKM | |
| SCHEMBL29627077 | 0.84 | GRM2 (0.47) | FEN1ALOX5APMPLKDM1AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772210-A | Iridium complex and preparation method and application thereof | 深圳市第二人民医院(深圳市转化医学研究院) | 2024-10-15 | — | — | CN | claimed |
| CN-113195728-B | Pharmaceutical process and intermediates | 阿斯利康(瑞典)有限公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240124770-A1 | COMPOUND, GUEST MATERIAL OF LIGHT-EMITTING LAYER, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | BEIJING NORMAL UNIVERSITY (CN) | 2024-04-18 | — | — | US | claimed |
| CN-117430643-A | Preparation method of ionic iridium (III) complex photooxidation reduction catalyst | 云南贵金属实验室有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116768788-A | Method for continuously synthesizing pyridine compound by adopting micro-channel reaction device through photoinduction | 南京工业大学 | 2023-09-19 | — | — | CN | claimed |
| CN-116744909-A | Metal organic frameworks deliver small and biological macromolecules for cancer immunotherapy | 芝加哥大学 | 2023-09-12 | — | — | CN | claimed |
| EP-4138784-A1 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | The University of Chicago (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2022166889-A1 | COMPOUND, GUEST MATERIAL OF LIGHT-EMITTING LAYER, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE | 北京师范大学 | 2022-08-11 | — | — | WO | claimed |
| CN-114751919-A | Cyclobutane fused spiro indoline compound as well as preparation method and application thereof | 华南理工大学 | 2022-07-15 | — | — | CN | claimed |
| CN-106478733-A | A kind of ionic type iridium metal complex electroluminescent material and its application | 中南大学 | 2017-03-08 | — | — | CN | claimed |
| WO-2026107178-A1 | GLOBAL AFFINITY PROFILING OF MOLECULAR INTERACTIONS USING COMPETITIVE ENRICHMENT | CORNELL UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | US | disclosed |
| EP-4294781-B1 | CATALYTIC METHOD FOR THE PREPARATION OF PERFLUOROALKOXY-SUBSTITUTED ARENES AND HETEROARENES | UNIV BERLIN FREIE (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | BIO-RAD LABORATORIES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | BIO-RAD LABORATORIES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7399857-B2 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060224007-A1 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY | 2006-10-05 | — | — | US | disclosed |
| US-20060223997-A1 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | CAD, NCLN, CCL5 | FEN1 653/4885ALOX5AP 2775/4885MPL 1568/4885 |
| US-20060223997-A1 | Synthesis of organometallic cyclometallated transition metal complexes | IMMT, AP3M1, AP1M1 | FEN1 1293/4885ALOX5AP 4102/4885MPL 1199/4885 |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | CBR1, CBR3, CYC1 | FEN1 878/4885ALOX5AP 2699/4885MPL 4704/4885 |
| US-12624033-B2 | KRAS inhibitors | KRAS, NRAS, BRAF | FEN1 1691/4885ALOX5AP 4178/4885MPL 1653/4885 |
| US-20060224007-A1 | Synthesis of organometallic cyclometallated transition metal complexes | IMMT, AP3M1, AP1M1 | FEN1 1293/4885ALOX5AP 4102/4885MPL 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.